

## **Risk stratification of patients with autoimmune rheumatic diseases**

To be used in conjunction with BSR guidance published 22 March 2020

### **KEY**

**Score of 3 or more: patients to shield**

**Score of 2: patients to self-isolate or maintain social distance at their discretion**

**Score of 1 or less: patients to maintain social distance**

<b>Risk factor</b>	<b>Score</b>
Corticosteroid dose of $\geq 20$ mg (0.5mg/kg) prednisolone (or equivalent) per day for more than four weeks	3
Corticosteroid dose of $\geq 5$ mg prednisolone but $< 20$ mg (or equivalent) per day for more than four weeks	2
Cyclophosphamide at any dose orally or IV within last six months	3
One immunosuppressive medication*, biologic/monoclonal** or small molecule immunosuppressant***	1
Two or more immunosuppressive medication*, biologic/monoclonal** or small molecule immunosuppressant***	2
Any one or more of these: age $> 70$ , Diabetes Mellitus, pre-existing lung disease, renal impairment, history of ischaemic heart disease or hypertension	1
Hydroxychloroquine, Sulfasalazine alone or in combination	0

\* Immunosuppressive medications include: Azathioprine, Leflunomide, Methotrexate, Mycophenolate (mycophenolate mofetil or mycophenolic acid), ciclosporin, Tacrolimus, Sirolimus. It does **NOT** include Hydroxychloroquine or Sulphasalazine, either alone or in combination.

\*\* Biologic/monoclonal includes: Rituximab within last 12 months; all anti-TNF drugs (etanercept, adalimumab, infliximab, golimumab, certolizumab and biosimilar variants of all of these); Tocilizumab; Abatacept; Belimumab; Anakinra; Seukinumab; Ixekizumab; Ustekinumab; Sarilumumab; Canakinumab

\*\*\* Small molecules includes: all JAK inhibitors – baracitinib, tofacitinib etc

\*\*\*\* Co-morbidity includes: age  $> 70$ , Diabetes Mellitus, any pre-existing lung disease, renal impairment, any history of Ischaemic Heart Disease or hypertension. Patients who have rheumatoid arthritis (RA) or CTD-related interstitial lung disease (ILD) are at additional risk and may need to be placed in the shielding category. All patients with pulmonary hypertension are placed in the shielding category.